A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Latest Information Update: 18 Dec 2024
At a glance
- Drugs Casimersen (Primary) ; Golodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms ESSENCE
- Sponsors Sarepta Therapeutics
Most Recent Events
- 01 Oct 2024 Planned End Date changed from 3 Oct 2025 to 17 Oct 2025.
- 01 Oct 2024 Planned primary completion date changed from 3 Oct 2025 to 15 Nov 2024.
- 03 Apr 2024 This study has been completed in Germany, according to European Clinical Trials Database record.